Page last updated: 2024-12-07

zk 112993

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ZK 112993: RN refers to (11beta, 17beta)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121874
SCHEMBL ID3860021
MeSH IDM0178601

Synonyms (13)

Synonym
zk 112993
zk 112,993
estra-4,9-dien-3-one, 11-(4-acetylphenyl)-17-hydroxy-17-(1-propynyl)-, (11beta,17beta)-
(8s,11r,13s,14s,17s)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
1ezj25pz5x ,
105114-63-4
unii-1ezj25pz5x
estra-4,9-dien-3-one, 11-(4-acetylphenyl)-17-hydroxy-17-(1-propyn-1-yl)-, (11.beta.,17.beta.)-
zk-112993
estra-4,9-dien-3-one, 11-(4-acetylphenyl)-17-hydroxy-17-(1-propynyl)-, (11.beta.,17.beta.)-
SCHEMBL3860021
Q27252342
AKOS040749845
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.17)18.7374
1990's21 (87.50)18.2507
2000's2 (8.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.70 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index5.96 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (96.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]